Zydus Lifesciences Limited has announced the execution of undertakings from seven shareholders to tender a total of 2,236,911 shares of Amplitude Surgical SA. These shares represent approximately 4.7% of Amplitude Surgical’s capital and voting rights.
This development follows Zydus Lifesciences’ announcement on March 11, 2025, regarding its planned tender offer for shares of the France-based medical technology company. In addition to these newly secured undertakings, Zydus has already arranged to acquire 85.6% of Amplitude Surgical’s capital from PAI Partners, company management, and two minority shareholders.
With both the block acquisition and the new undertakings in place, Zydus Lifesciences would be positioned to hold more than 90% of Amplitude Surgical’s capital and voting rights upon completion of the offer.
The undertakings to tender may be revoked if a competing offer is submitted by a third party, deemed compliant, and subsequently opened by the French financial markets authority, Autorité des marchés financiers (AMF).
Completion of the 85.6% stake acquisition is expected by June 2025, pending regulatory approvals. Zydus Lifesciences intends to file the draft tender offer with the AMF upon receiving the necessary clearances. The formal opening of the tender offer will remain subject to AMF’s clearance decision.